Form: 8-K

Current report filing

November 22, 2019

RESMED INC US false 0000943819 0000943819 2019-11-21 2019-11-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 21, 2019

Date of Report (Date of earliest event reported)

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-15317

 

98-0152841

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

9001 Spectrum Center Boulevard

San Diego, California 92123

(Address of Principal Executive Offices) (Zip Code)

 

 

(858) 836-5000

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.004 per value

 

RMD

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On November 21, 2019, at our annual meeting of stockholders, our stockholders (1) elected the three nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2020; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”).

 

For

   

Against

   

Abstain

   

Broker
Non-Votes

 

Item of Business No. 1: Elect the following three nominees to serve for

three-year terms until our annual meeting of stockholders in 2022:

   

     

     

     

 

Carol Burt

   

107,734,172

     

1,255,799

     

169,663

     

6,405,499

 

Jan De Witte

   

108,960,896

     

63,450

     

135,288

     

6,405,499

 

Rich Sulpizio

   

105,184,218

     

3,855,596

     

119,820

     

6,405,499

 
                         

 

For

   

Against

   

Abstain

   

Broker
Non-Votes

 

Item No. 2: Ratify KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2020.

   

112,545,822

     

2,886,007

     

133,304

     

 
                         

 

For

   

Against

   

Abstain

   

Broker
Non-Votes

 

Item No.3: Approve, on an advisory basis, the compensation of ResMed’s named executive officers.

   

96,498,840

     

12,525,801

     

134,993

     

6,405,499

 


SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

RESMED INC.

         

Date: November 22, 2019

 

By:

 

/s/ David Pendarvis

 

 

David Pendarvis

 

 

Chief administrative officer, global general counsel and secretary